Anti-interferon-γ autoantibodies: immunopathogenesis, diagnostic innovation, and emerging therapeutic strategies in an adult-onset immunodeficiency. (PubMed, Front Immunol) - Oct 16, 2026 - "We propose a clinical decision pathway in which refractory or progressive infection, rather than a fixed titer threshold, triggers immunomodulation, with rituximab and cyclophosphamide as the best-supported induction strategies, daratumumab reserved for refractory cases, and emerging AIGA-specific evidence supporting azathioprine for maintenance. We also highlight emerging antigen-specific strategies, including chimeric autoantibody receptor T cells engineered to eliminate autoantibody-producing B cells, as a future direction toward durable remission. Finally, we outline priorities for prospective validation and biomarker-guided therapy."
Biomarker • Journal • Review • Human Immunodeficiency Virus • Immunology • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases • IFNG
|
|
Aristine Cheng; Chin-Shiang Tsai; Farha Naz
|